<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="rapid-communication"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Med Chem Lett</journal-id><journal-id journal-id-type="iso-abbrev">ACS Med Chem Lett</journal-id><journal-id journal-id-type="publisher-id">ml</journal-id><journal-id journal-id-type="coden">amclct</journal-id><journal-title-group><journal-title>ACS Medicinal Chemistry Letters</journal-title></journal-title-group><issn pub-type="epub">1948-5875</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10726451</article-id><article-id pub-id-type="doi">10.1021/acsmedchemlett.3c00369</article-id><article-categories><subj-group><subject>Letter</subject></subj-group></article-categories><title-group><article-title>MAIP: An
Open-Source Tool to Enrich High-Throughput
Screening Output and Identify Novel, Druglike Molecules with Antimalarial
Activity</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3562-1328</contrib-id><name><surname>Bosc</surname><given-names>Nicolas</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5512-6810</contrib-id><name><surname>Felix</surname><given-names>Eloy</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9322-1181</contrib-id><name><surname>Gardner</surname><given-names>J. Mark F.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2567-3872</contrib-id><name><surname>Mills</surname><given-names>James</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Timmerman</surname><given-names>Martijn</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Asveld</surname><given-names>Dennis</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Rensen</surname><given-names>Kim</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Mukherjee</surname><given-names>Partha</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Das</surname><given-names>Rishi</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath10"><name><surname>Chenu</surname><given-names>Elodie</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath11"><name><surname>Besson</surname><given-names>Dominique</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath12"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8448-6068</contrib-id><name><surname>Burrows</surname><given-names>Jeremy N.</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath13"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9447-8982</contrib-id><name><surname>Duffy</surname><given-names>James</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath14"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7530-2113</contrib-id><name><surname>Laleu</surname><given-names>Beno&#x000ee;t</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath15"><name><surname>Guantai</surname><given-names>Eric M.</given-names></name><xref rid="aff7" ref-type="aff">&#x000b6;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath16"><name><surname>Leach</surname><given-names>Andrew R.</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>European
Molecular Biology Laboratory, <institution>European Bioinformatics
Institute (EMBL-EBI)</institution>, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, <country>United Kingdom</country></aff><aff id="aff2"><label>&#x02021;</label><institution>AMG
Consultants Ltd</institution>, Discovery
Park House, Discovery Park, Sandwich, Kent CT13 9ND, <country>United Kingdom</country></aff><aff id="aff3"><label>&#x000a7;</label><institution>Sandexis
Medicinal Chemistry Ltd</institution>, Innovation House, Discovery Park, Sandwich, Kent CT13 9FF, <country>United Kingdom</country></aff><aff id="aff4"><label>&#x02225;</label><institution>Pivot
Park Screening Centre</institution>, Pivot Park (Frederick Banting Building), Kloosterstraat 9, 5349 AB Oss, <country>The Netherlands</country></aff><aff id="aff5"><label>&#x022a5;</label><institution>TCG
Life Sciences, Bengal Intelligent Park Limited</institution>, Block EP &#x00026; GP, Salt Lake Electronics
Complex, Sector V, Kolkata, West Bengal 700091, <country>India</country></aff><aff id="aff6"><label>#</label><institution>Medicines
for Malaria Ventures</institution>, 1215 Geneva, <country>Switzerland</country></aff><aff id="aff7"><label>&#x000b6;</label>Department
of Pharmacy, Faculty of Health Sciences, <institution>University of Nairobi</institution>, 00202 Nairobi, <country>Kenya</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>duffyj@mmv.org</email>.</corresp><corresp id="cor2"><label>*</label>Email: <email>arl@ebi.ac.uk</email>.</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="collection"><day>14</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>11</month><year>2023</year></pub-date><volume>14</volume><issue>12</issue><fpage>1733</fpage><lpage>1741</lpage><history><date date-type="received"><day>29</day><month>08</month><year>2023</year></date><date date-type="accepted"><day>06</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>30</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00369_0006" id="ab-tgr1"/></p><p>Efforts to tackle malaria must continue for a disease
that threatens
half of the global population. Parasite resistance to current therapies
requires new chemotypes that are able to demonstrate effectiveness
and safety. Previously, we developed a machine-learning-based approach
to predict compound antimalarial activity, which was trained on the
compound collections of several organizations. The resulting prediction
platform, MAIP, was made freely available to the scientific community
and offers a solution to prioritize molecules of interest in virtual
screening and hit-to-lead optimization. Here, we experimentally validate
MAIP and demonstrate how the approach was used in combination with
a robust compound selection workflow and a recently introduced innovative
high-throughput screening (HTS) cascade to select and purchase compounds
from a public library for subsequent experimental screening. We observed
a 12-fold enrichment compared with a randomly selected set of molecules,
and the eight hits we ultimately selected exhibit good potency and
absorption, distribution, metabolism, and excretion (ADME) profiles.</p></abstract><kwd-group><kwd>Malaria</kwd><kwd>Antimalarial Drug Discovery</kwd><kwd>QSAR</kwd><kwd>High-Throughput Screening</kwd><kwd>Screening Cascade</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Bill and Melinda Gates Foundation</institution><institution-id institution-id-type="doi">10.13039/100000865</institution-id></institution-wrap></funding-source><award-id>INV-007155</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>European Molecular Biology Laboratory</institution><institution-id institution-id-type="doi">10.13039/100013060</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ml3c00369</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ml3c00369</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta><notes id="NOTES-d14e310-autogenerated"><fn-group><fn fn-type="after-asap" id="d33e202"><p>This paper was published ASAP on
November 23, 2023, with a duplicate of reference 22. The corrected
version was reposted November 27, 2023.</p></fn></fn-group></notes></front><body><p>Malaria is a life-threatening
infectious disease caused by parasites of the <italic>Plasmodium</italic> genus that are transmitted to people through the bites of infected
female <italic>Anopheles</italic> mosquitoes. Despite considerable
progress with prevention and treatment interventions, half of the
world&#x02019;s population is still threatened by malaria, mainly in
Africa but also in Southeast Asia and Central and South America.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> There is growing evidence that the effect of artemisinin-based combination
therapies (ACTs) is being diminished by decreasing parasite clearance
rates of artemisinin derivatives and also partner drug resistance.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup><italic>De novo</italic> artemisinin partial
resistance has now also been observed in Africa, though ACTs remain
effective.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref4">4</xref></sup> Consequently, there is a focus on the delivery
of new, efficacious, affordable, and safe medicines with multiple
key objectives that include overcoming future ACT resistance;<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> blocking the parasite life cycle by interrupting
transmission from vector to host and <italic>vice versa</italic>;
and targeting malaria species that remain dormant in the liver.</p><p>In parallel, a promising vaccine (RTS,S/AS01) has recently been
recommended by the World Health Organization (WHO) for children from
5 months of age on the basis of previous encouraging results in several
clinical trials.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> A new vaccine candidate
(R21/MatrixM) is also demonstrating high-level efficacy in combination
with seasonal malaria chemoprevention and standard measures.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Hence, chemoprevention remains an important tool
in the prevention of malaria and enhancement of malaria control.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> The past two decades have seen significant collaboration
and open science activity in tackling the malaria challenge. One such
innovation involves screening large compound libraries in highly efficient
high-throughput screening platforms and then making the results freely
available in the literature.<sup><xref ref-type="bibr" rid="ref9">9</xref>&#x02212;<xref ref-type="bibr" rid="ref11">11</xref></sup> Phenotypic whole-cell assays
have been widely used to identify compounds that affect parasite growth
and viability during the asexual blood stage of the <italic>Plasmodium</italic> spp. infection. These efforts have led to the identification of
multiple candidate drugs that have progressed to clinical development.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup></p><p>Quantitative structure&#x02013;activity
relationship (QSAR) modeling
and, more generally, machine learning techniques are widely used in
drug discovery.<sup><xref ref-type="bibr" rid="ref13">13</xref>&#x02212;<xref ref-type="bibr" rid="ref15">15</xref></sup> In the context of high-throughput screening, these
methods enable the virtual screening of large collections of compounds
to quickly assess their therapeutic potential and prioritize for experimental
validation. Unsurprisingly, antimalaria drug discovery is making extensive
use of machine learning. For example, methods such as deep learning
can be employed to identify novel antimalarial molecules.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Similar techniques, together with more conventional
QSAR models, have also been used recently in an open competition to
predict new malaria inhibitors, sometimes exhibiting unusual chemical
motifs.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup></p><p>The work described here
builds on a collaboration between large
pharmaceutical companies and not-for-profit organizations to deliver
a consensus modeling approach in which multiple proprietary compound
libraries were combined without ever sharing structures of the actual
molecules.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> This partnership resulted
in the open MAlaria Inhibitor Prediction (MAIP) web platform, which
scores compounds using a consensus model derived from 6.5 million
malaria bioactivity values from 11 compound collections.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Hosted by the European Bioinformatics Institute
(EMBL-EBI), this free tool was assessed by predicting three diverse
validation sets showing hit rate enrichment &#x0003e; 2 in each case. However,
to date, no prospective experimental validation has been published
that demonstrates the ability of MAIP in prioritizing new potent malaria
inhibitors.</p><p>Herein, we aim to address this point by presenting
a large-scale
computational and experimental project to validate MAIP and the related
modeling consensus approaches that were developed in parallel.</p><p>We used the previously introduced MAIP platform to predict the
whole 7.6 M compound collection from MolPort (accessed in November
2019).<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> A brief description of the modeling
approach is available in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00369/suppl_file/ml3c00369_si_001.pdf">Supporting Information</ext-link>. The molecules were predicted using the MAIP platform in addition
to two derived consensus approaches. The resulting scores for the
three methods (MaxScore, MinRank, and MetaModel) were used to select
166&#x0202f;000 unique compounds by combining the top 80&#x0202f;000
from each of them. To focus the library on potential novel hits, we
applied an exclusion protocol on the basis of several criteria. Compounds
similar to existing antimalarial compounds from the Medicines for
Malaria Venture (MMV) collections were removed. Compounds containing
unwanted moieties (PAINS,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> toxicophores,
etc.) were filtered out. To focus the collection in druglike chemical
space, a molecular weight between 200 and 550 and a clogP between
0 and 5.5 were considered as prerequisites for the compounds. To further
reduce the size of the collection while preserving structural diversity,
we performed unsupervised clustering by selecting up to three compounds
per cluster. In parallel, to assess the performance of the compound
scoring, 45&#x0202f;000 compounds were randomly picked from the three
prediction methods disregarding their antimalarial scores, and the
same protocol was applied.</p><p>The total selection of about 20&#x0202f;700
compounds (scored +
randomly selected) was evaluated for commercial availability for the
acquisition of 2 &#x003bc;mol of samples to be delivered within 4 weeks
to the MMV compound management partner. About 19&#x0202f;750 of the
listed molecules could be delivered within the required timeline and
met the expected minimum 90% purity criterion.</p><p>To further reduce
the list of compounds for acquisition, we performed
a multiparameter optimization on the basis of the similarity, the
price, and the vendors to prioritize 6000 of them where 4730 resulted
from the scored compounds and 1270 from the randomly selected set.
A total of 5930 commercially available molecules were purchased with
a ratio of scored versus randomly selected molecules maintained at
3.95:1. Ultimately 5850 samples were delivered to the MMV compound
management partner. The 80 undelivered samples were found to be out
of stock at the time of acquisition.</p><p>This collection is termed
the ChEMBL QSAR Library (CQL). Its molecular
property profile shows a focus on drug likeness (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref> A&#x02013;H). After the selection,
we observed that the majority of compounds were selected from the
MetaModel scoring, followed by MaxScore, NoScore (random selection),
and MinRank (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref> I). The MetaModel consensus has already been implemented in the
MAIP web platform (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ebi.ac.uk/chembl/maip/">www.ebi.ac.uk/chembl/maip/</uri>).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>CQL molecular property profiles. Ideal values for each criterion
are depicted in green, acceptable ones in orange, and nonideal ones
in red. (A) Molecular weight (MW); (B) log of the coefficient of partition
between octanol and water (LogP); (C) number of structural alerts;
(D) number of hydrogen bond donors (HBD); (E) number of hydrogen bond
acceptors (HBA); (F) number of rotatable bonds; (G) multiparameter
optimization (MPO) score; (H) molecular class; and (I) CQL breakdown
on the basis of the compound selection reason.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00369_0001" id="gr1" position="float"/></fig><p>All the training sets used to develop the predictive
models remained
undisclosed, thereby making it impossible to determine if the selected
compounds had already been tested for antimalarial activity by our
previous project partners. However, our model consensus approaches
were already assessed using three different validation sets.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Comparing the chemical spaces of these libraries
with the CQL, we can see how similar they are. Therefore, we visualized
the chemical space represented by the CQL using the t-distributed
Stochastic Neighbor Embedding (t-SNE) algorithm<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> and superimposed this onto the chemical space of the data
sets previously used to validate our modeling approach (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). For details on the usage
of the t-SNE method and the validation sets, the reader is invited
to refer to our previous work.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>t-distributed
Stochastic Neighbor Embedding representation showing
the chemical space of the CQL library and comparing it with the chemical
space of the three validation sets used to validate MAIP. St. Jude
Screening Set: inactive compounds, light green; active compounds,
green. PubChem: inactive compounds, light red; active compounds, red.
MMV test set: inactive compounds, light blue; active compounds, blue;
selected compounds for this study, yellow; active experimentally validated,
black.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00369_0002" id="gr2" position="float"/></fig><p>The CQL chemical space broadly overlaps with the
St. Jude Screening
set for both active and inactive compounds. In the validation stage
of our consensus approaches, we observed it was the validation set
with the highest ROC AUC scores (0.82, 0,79, and 0.73 for the MetaModel,
MaxScore, and MinRank consensus, respectively). It also overlaps locally
with the chemical spaces of the MMV and PubChem sets. These results
suggest that the CQL remains in a chemical space relatively close
to that observed and validated. This is not necessarily unexpected
nor a limitation, as predictive models are well known to be better
at predicting compounds in their domain of applicability. Nevertheless,
this will be relevant to subsequent work to analyze the novelty of
our hit molecules, which are described in more detail below.</p><p>The MMV&#x02019;s <italic>Plasmodium falciparum</italic> (<italic>P. falciparum</italic>) asexual blood stage phenotypic screening
cascade was developed to identify and prioritize novel, high-quality
compounds with potential as start points for further development in
antimalarial drug discovery projects. The high-throughput screening
(HTS) cascade contains orthogonal efficacy and cytotoxicity assays.
A recent report describes the use of this screening cascade to screen
141&#x0202f;786 compounds from which 33 antimalarial molecules with
a robust data package and potential for further development (&#x0201c;Confirmed
Actives&#x0201d;) were identified.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></p><p>Here, this state of the art screening platform was applied to CQL
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>). During
solubilization and reformatting activities, 40 samples were identified
with solubility issues and removed from the screening set, thereby
leaving 5810 compounds (4623 scored + 1187 randomly selected). A primary
screen was conducted at a single concentration (2 &#x003bc;M) against <italic>P. falciparum</italic> NF54 (nanoGlo readout over 72 h incubation).
A total of 223 compounds (215 predicted active, eight randomly selected,
equivalent to a 7-fold enrichment of hit rate for the predicted active
compounds compared with the random compounds) had a <italic>Z</italic>-score lower or equal to the cutoff value of &#x02212;4 and were further
retested in two confirmatory orthogonal <italic>P. falciparum</italic> NF54 assays (nanoGlo and pLDH readouts over 72 h incubation). A
total of 145 (142 + 3 12-fold enrichment) compounds showed a growth
inhibition activity greater than 30% in at least one of the two assays.
These compounds were then tested in five-point dose&#x02013;response
curve (DRC) assays, each of which provides key information to decide
which compound(s) to progress (highlighted in blue). Five different
assays were carried out, including three parasite growth assays over
72 h of incubation (<italic>P. falciparum</italic> NF54 in both nanoGlo
and pLDH read-outs and <italic>P. falciparum</italic> Dd2 in pLDH
read-out), one parasite growth assay over 12 h of incubation (<italic>P. falciparum</italic> NF54 in nanoGlo read-out) in order to evaluate
the speed of action, and a cytotoxicity assay against human HepG2
cells over 72 h of incubation. Out of 36 screening active compounds
(36 + 0) fulfilling all of the ideal criteria, 12 were deemed attractive
in terms of chemical novelty and diversity for further progression
and evaluation. This set of compounds was further complemented with
others that passed at least three of the five DRC criteria, together
with assessments of chemical novelty and diversity, which led to 33
selected compounds. Twenty-two compounds (those still available from
commercial suppliers) were repurchased, and the compound efficacy
was retested against <italic>P. falciparum</italic> 3D7 (pLDH readout
over 72 h incubation) and human HepG2 cells over 72 h of incubation
at a different testing center. This stringent cascade resulted in
the identification of eight compounds with an IC<sub>50</sub> lower
than 2 &#x003bc;M in <italic>P. falciparum</italic> 3D7, higher than
10 &#x003bc;M in HepG2, and fulfilling the MMV Confirmed Active criteria
(<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mmv.org/frontrunner-templates">https://www.mmv.org/frontrunner-templates</uri>), as determined in two independent test centers (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Identification and prioritization
of hits from the ChEMBL QSAR
library (CQL). Strict selection criteria are depicted in green, and
ideal ones are in blue. For each step, the number of scored compounds
is indicated in red. In black is the number of compounds randomly
selected.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00369_0003" id="gr3" position="float"/></fig><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Structures of the eight Confirmed Actives identified with
the MMV&#x02019;s <italic>P. falciparum</italic> asexual blood stage
phenotypic screening platform.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00369_0004" id="gr4" position="float"/></fig><p>As a result of the selection criteria, the eight
Confirmed Actives
have attractive physicochemical and biological properties and are
suitable for further optimization (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). All compounds have equivalent potency
(within 3-fold) between the drug-sensitive (<italic>P. falciparum</italic> 3D7) and drug-resistant (Dd2) strains. Importantly, the results
in HepG2 cell viability assays performed in two different laboratories
confirm the lack of cytotoxicity of these compounds, and no structural
features likely to be associated with toxicity or assay interference
were found.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Confirmed Actives: Calculated Physicochemical
Properties, Potency (<italic>P. falciparum</italic> 3D7), and Cell
Viability (HepG2)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">compound ID</th><th style="border:none;" align="center" char=".">MW</th><th style="border:none;" align="center" char=".">LogP</th><th style="border:none;" align="center" char=".">3D7 LDH (72&#x000a0;h) IC50 (&#x003bc;M)</th><th style="border:none;" align="center" char=".">Dd2 LDH (72&#x000a0;h) IC50 (&#x003bc;M)</th><th style="border:none;" align="center" char=".">HepG2 (72&#x000a0;h) IC<sub>50</sub> (&#x003bc;M)</th></tr></thead><tbody><tr><td style="border:none;" align="left">MMV1797331</td><td style="border:none;" align="char" char=".">357</td><td style="border:none;" align="char" char=".">2.0</td><td style="border:none;" align="char" char=".">1.9</td><td style="border:none;" align="char" char=".">2.0</td><td style="border:none;" align="char" char=".">21.6</td></tr><tr><td style="border:none;" align="left">MMV1797658</td><td style="border:none;" align="char" char=".">335</td><td style="border:none;" align="char" char=".">3.2</td><td style="border:none;" align="char" char=".">0.78</td><td style="border:none;" align="char" char=".">1.5</td><td style="border:none;" align="char" char=".">22.1</td></tr><tr><td style="border:none;" align="left">MMV1797951</td><td style="border:none;" align="char" char=".">371</td><td style="border:none;" align="char" char=".">3.1</td><td style="border:none;" align="char" char=".">1.0</td><td style="border:none;" align="char" char=".">0.98</td><td style="border:none;" align="char" char=".">13.8</td></tr><tr><td style="border:none;" align="left">MMV1798925</td><td style="border:none;" align="char" char=".">342</td><td style="border:none;" align="char" char=".">3.4</td><td style="border:none;" align="char" char=".">1.1</td><td style="border:none;" align="char" char=".">1.5</td><td style="border:none;" align="char" char=".">19.1</td></tr><tr><td style="border:none;" align="left">MMV1798946</td><td style="border:none;" align="char" char=".">427</td><td style="border:none;" align="char" char=".">2.5</td><td style="border:none;" align="char" char=".">0.75</td><td style="border:none;" align="char" char=".">2.0</td><td style="border:none;" align="char" char=".">&#x0003e;25</td></tr><tr><td style="border:none;" align="left">MMV1799348</td><td style="border:none;" align="char" char=".">397</td><td style="border:none;" align="char" char=".">2.8</td><td style="border:none;" align="char" char=".">1.1</td><td style="border:none;" align="char" char=".">2.7</td><td style="border:none;" align="char" char=".">&#x0003e;25</td></tr><tr><td style="border:none;" align="left">MMV1801316</td><td style="border:none;" align="char" char=".">359</td><td style="border:none;" align="char" char=".">3.6</td><td style="border:none;" align="char" char=".">1.5</td><td style="border:none;" align="char" char=".">3.6</td><td style="border:none;" align="char" char=".">&#x0003e;25</td></tr><tr><td style="border:none;" align="left">MMV1802771</td><td style="border:none;" align="char" char=".">424</td><td style="border:none;" align="char" char=".">3.0</td><td style="border:none;" align="char" char=".">0.81</td><td style="border:none;" align="char" char=".">1.1</td><td style="border:none;" align="char" char=".">20.0</td></tr></tbody></table></table-wrap><p>As part of the Confirmed Active data profiling, the
eight compounds
were tested in an early absorption, distribution, metabolism, and
excretion (ADME) package (LogD, aqueous solubility, human microsomal
stability, and rat hepatocytes stability) (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). The ADME data generated are not used as
strict selection criteria but as a guide for hit validation and to
flag potential issues that may need to be addressed early in the project
as part of the hit-to-lead optimization process. As a result of the
CQL library design process, the compounds have acceptable lipophilicity
with no compound with a LogD &#x0003e; 4 and several in the range (LogD
=
1&#x02013;3) usually associated with good oral bioavailability. Encouragingly,
the compounds have low to moderate clearance in both human liver microsomes
and rat hepatocytes, thereby indicating that the scaffolds are not
inherently unstable and that they have potential to be optimized into
drug leads with the long duration required for single-dose antimalarial
treatment or prophylaxis. In addition, as stated earlier, these eight
compounds do not interfere with hepatic cell viability.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>ADME Properties of the Eight Confirmed
Actives</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">compound ID</th><th style="border:none;" align="center" char=".">LogD
pH 7.4</th><th style="border:none;" align="center" char=".">kinetic solubility (&#x003bc;M)</th><th style="border:none;" align="center" char=".">human liver microsomes CLint (&#x003bc;L/min/mg)</th><th style="border:none;" align="center" char=".">rat
hepatocytes CLint (&#x003bc;L/min/10<sup>6</sup>&#x000a0;cells)</th></tr></thead><tbody><tr><td style="border:none;" align="left">MMV1797331</td><td style="border:none;" align="char" char=".">1.0</td><td style="border:none;" align="char" char=".">200</td><td style="border:none;" align="char" char=".">3.7</td><td style="border:none;" align="char" char=".">1.9</td></tr><tr><td style="border:none;" align="left">MMV1797658</td><td style="border:none;" align="char" char=".">0.5</td><td style="border:none;" align="char" char=".">200</td><td style="border:none;" align="char" char=".">3.5</td><td style="border:none;" align="char" char=".">7.2</td></tr><tr><td style="border:none;" align="left">MMV1797951</td><td style="border:none;" align="char" char=".">&#x02013;0.2</td><td style="border:none;" align="char" char=".">200</td><td style="border:none;" align="char" char=".">8.3</td><td style="border:none;" align="char" char=".">1.4</td></tr><tr><td style="border:none;" align="left">MMV1798925</td><td style="border:none;" align="char" char=".">0.3</td><td style="border:none;" align="char" char=".">173</td><td style="border:none;" align="char" char=".">3.5</td><td style="border:none;" align="char" char=".">7.2</td></tr><tr><td style="border:none;" align="left">MMV1798946</td><td style="border:none;" align="char" char=".">2.9</td><td style="border:none;" align="char" char=".">170</td><td style="border:none;" align="char" char=".">14</td><td style="border:none;" align="char" char=".">2</td></tr><tr><td style="border:none;" align="left">MMV1799348</td><td style="border:none;" align="char" char=".">1.2</td><td style="border:none;" align="char" char=".">198</td><td style="border:none;" align="char" char=".">3.5</td><td style="border:none;" align="char" char=".">1.2</td></tr><tr><td style="border:none;" align="left">MMV1801316</td><td style="border:none;" align="char" char=".">2.8</td><td style="border:none;" align="char" char=".">86</td><td style="border:none;" align="char" char=".">24.1</td><td style="border:none;" align="char" char=".">2.7</td></tr><tr><td style="border:none;" align="left">MMV1802771</td><td style="border:none;" align="char" char=".">1.0</td><td style="border:none;" align="char" char=".">100</td><td style="border:none;" align="char" char=".">11</td><td style="border:none;" align="char" char=".">2.6</td></tr></tbody></table></table-wrap><p>Machine learning and artificial intelligence models
can be criticized
for not being able to predict compounds far enough from the chemical
space they are trained on.<sup><xref ref-type="bibr" rid="ref24">24</xref>&#x02212;<xref ref-type="bibr" rid="ref28">28</xref></sup> This can lead to the discovery of &#x0201c;new&#x0201d; compounds
too close to existing drugs and showing similar modes of action but
also adverse events. In the research for new leads to fight ACT resistance,
new chemotypes are a prerequisite for killing the parasite.</p><p>In the absence of knowledge regarding the model training sets due
to confidentiality reasons, we were able to directly compare only
the eight Confirmed Actives with the MMV compound library. Similar
compounds in the 80%&#x02013;90% window were found only for MMV1797951
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00369/suppl_file/ml3c00369_si_001.pdf">Table S1</ext-link>).</p><p>Additionally we ran a
comparison against the ChEMBL database to
determine, first, if these compounds are chemically close to already
published molecules and, second, if these similar compounds have been
tested on <italic>P. falciparum</italic>.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> Using the Python package FPsim2 with Morgan fingerprints, radius
2, 2048 bits, and enabled features, we measured the Tversky similarity
between the eight hits and the whole ChEMBL database (version 32).</p><p>Among the two hits with similar ChEMBL compounds in the 70%&#x02013;80%
and 80%&#x02013;90% ranges, there was no evidence of any antimalarial
activity for the compounds related to MMV1797331 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>). However, moderately similar
compounds to MMV1799348 were found to be active on <italic>P. falciparum</italic> 3D7. Five other hits have similar ChEMBL compounds only in the 70%&#x02013;80%
range, MMV1802771, MMV1798925, MMV1797951, MMV1801316, and MMV1798946,
for which moderate biological activities in <italic>P. falciparum</italic> phenotypic assays were found for the first four of them (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>). When looking closely
at MMV1801316 and its similar compound CHEMBL3476473, we observed
they differ only by two atoms with a methylindole rather than a hydroxyquinoline,
a difference that may nevertheless be significant in medicinal chemistry.
Finally, we did not retrieve any similar compounds for MMV1797658.</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Examples
of similar compounds found in ChEMBL tested against <italic>P. falciparum</italic> and binned by the Tversky similarity ranges.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00369_0005" id="gr5" position="float"/></fig><p>Our comparisons suggest that some of the hits identified
here represent
structurally novel potential starting points for the development of
new drugs targeting <italic>P. falciparum</italic> and, in particular,
MMV1797658, MMV1797331, and MMV1798946 solely on the basis of this
analysis. Indeed, there is no evidence in ChEMBL that they, or similar
compounds, have been tested previously on <italic>P. falciparum</italic> strains.</p><p>In conclusion, the work presented here demonstrates
how the combination
of <italic>in silico</italic> model predictions with a rigorous compound
selection workflow and a robust biological assay cascade can lead
to new chemotypes with the potential to deliver new drugs.</p><p>In
particular, we wish to highlight the performance of our <italic>in
silico</italic> MAIP model and the related consensus approaches
when compared with an equivalent compound set chosen using the same
unbiased rigorous criteria but with no preference toward predicted
antimalarial activity. Specifically, from the 4623 compounds selected
using the consensus approaches, we achieved a hit rate of 4.65% after
the primary screen. By comparison, the hit rate for the randomly selected
1187 compounds was 0.67%. When comparing the results obtained with
the confirmatory screen, the difference is even more noticeable with
hit rates of respectively 3.07% (142 active compounds) and 0.25% (3).
Hence, the CQL has been enriched in hit molecules (7-fold and 12-fold,
respectively, after the primary and confirmatory screen), while at
the same time keeping the size of the library relatively small. As
for compound novelty, different checkpoints in our workflows help
identify new chemical series that were never published as acting against <italic>P. falciparum</italic> to the best of our knowledge.</p><p>Finally,
these results demonstrate that the MAIP platform and its
associated consensus approaches can deliver compounds with good antimalarial
activity. This initial study provides critical experimental validation
of the approach and underlines the usefulness of MAIP for the whole
community. It is the hope of the project team that this inspires similar
work on other diseases that disproportionately affect the most vulnerable
members of the global population.</p><p>The experimental results will
be deposited in ChEMBL to allow the
scientific community to further benefit from this work.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup></p></body><back><notes id="notes-2" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsmedchemlett.3c00369?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsmedchemlett.3c00369</ext-link>.<list id="silist" list-type="simple"><list-item><p><italic>In silico</italic> model description, compound
scoring, compound selection, protocol of biological assays, examples
of known antimalarial scaffolds used to define compound attractiveness,
and compounds similar to the Confirmed Actives and found in the MMV
model training sets (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00369/suppl_file/ml3c00369_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00369_si_001.pdf"><caption><p>ml3c00369_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes-1"><title>Author Contributions</title><p>N.B. contributed
to the MAIP development and the compound selection and wrote the manuscript,
E.F. contributed to the MAIP development and the compound selection,
J.M.F.G. contributed to the compound selection, J.M. contributed to
the compound selection, P.M. was involved in culturing the parasite
strains and performing the pLDH assays, R.D. was involved in preparing
serial dilutions of the test compounds and determining the IC<sub>50</sub> values in the DRC assays, M.T. contributed to the HTS, D.A.
contributed to the HTS, K.R. contributed to the HTS, E.C. ran the
MMV HTS cascade, D.B. ordered the compounds and supervised their reformatting
before screening, J.N.B. contributed to the project design, J.D. contributed
to the project design and the selection of the Confirmed Actives and
wrote the manuscript, B.L. contributed to the selection of the Confirmed
Actives, E.M.G. was involved in retesting the compounds, and A.R.L.
contributed to the project design and supervised the manuscript writing.</p></notes><notes notes-type="COI-statement" id="NOTES-d14e768-autogenerated"><p>The authors declare no
competing financial interest.</p></notes><notes notes-type="" id="NOTES-d14e742-autogenerated"><title>Notes</title><p>The results of this
screening have been published in ChEMBL
(<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.6019/CHEMBL4888484">https://doi.org/10.6019/CHEMBL4888484</uri>).</p></notes><ack><title>Acknowledgments</title><p>We thank the Bill &#x00026; Melinda Gates Foundation
and the Member
States of the European Molecular Biology Laboratory for funding this
research work, and the Bill &#x00026; Melinda Gates Foundation for making
this work open access.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>ACT</term><def><p>artemisinin-based
combination therapies</p></def></def-item><def-item><term>CQL</term><def><p>ChEMBL QSAR library</p></def></def-item><def-item><term>DRC</term><def><p>dose&#x02013;response
curve</p></def></def-item><def-item><term>LogP</term><def><p>log of
the coefficient of partition between octanol and water</p></def></def-item><def-item><term>MAIP</term><def><p>malaria inhibitor prediction
platform</p></def></def-item><def-item><term>MPO</term><def><p>multiparameter
optimization</p></def></def-item><def-item><term><italic>P. falciparum</italic></term><def><p><italic>Plasmodium falciparum</italic></p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="book" id="cit1"><person-group><collab>World Health Organization</collab></person-group>. <source>World Malaria Report 2021</source>; <publisher-name>World Health
Organization</publisher-name>: <publisher-loc>Geneva</publisher-loc>, <year>2021</year>.</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Hakizimana</surname><given-names>D.</given-names></name>; <name><surname>Ntizimira</surname><given-names>C.</given-names></name>; <name><surname>Mbituyumuremyi</surname><given-names>A.</given-names></name>; <name><surname>Hakizimana</surname><given-names>E.</given-names></name>; <name><surname>Mahmoud</surname><given-names>H.</given-names></name>; <name><surname>Birindabagabo</surname><given-names>P.</given-names></name>; <name><surname>Musanabaganwa</surname><given-names>C.</given-names></name>; <name><surname>Gashumba</surname><given-names>D.</given-names></name>
<article-title>The Impact of Covid-19 on Malaria
Services in Three
High Endemic Districts in Rwanda: A Mixed-Method Study</article-title>. <source>Malar J.</source>
<year>2022</year>, <volume>21</volume> (<issue>1</issue>), <fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s12936-022-04071-3</pub-id>.<pub-id pub-id-type="pmid">35164781</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Imwong</surname><given-names>M.</given-names></name>; <name><surname>Dhorda</surname><given-names>M.</given-names></name>; <name><surname>Myo Tun</surname><given-names>K.</given-names></name>; <name><surname>Thu</surname><given-names>A. M.</given-names></name>; <name><surname>Phyo</surname><given-names>A. P.</given-names></name>; <name><surname>Proux</surname><given-names>S.</given-names></name>; <name><surname>Suwannasin</surname><given-names>K.</given-names></name>; <name><surname>Kunasol</surname><given-names>C.</given-names></name>; <name><surname>Srisutham</surname><given-names>S.</given-names></name>; <name><surname>Duanguppama</surname><given-names>J.</given-names></name>; <name><surname>Vongpromek</surname><given-names>R.</given-names></name>; <name><surname>Promnarate</surname><given-names>C.</given-names></name>; <name><surname>Saejeng</surname><given-names>A.</given-names></name>; <name><surname>Khantikul</surname><given-names>N.</given-names></name>; <name><surname>Sugaram</surname><given-names>R.</given-names></name>; <name><surname>Thanapongpichat</surname><given-names>S.</given-names></name>; <name><surname>Sawangjaroen</surname><given-names>N.</given-names></name>; <name><surname>Sutawong</surname><given-names>K.</given-names></name>; <name><surname>Han</surname><given-names>K. T.</given-names></name>; <name><surname>Htut</surname><given-names>Y.</given-names></name>; <name><surname>Linn</surname><given-names>K.</given-names></name>; <name><surname>Win</surname><given-names>A. A.</given-names></name>; <name><surname>Hlaing</surname><given-names>T. M.</given-names></name>; <name><surname>van der
Pluijm</surname><given-names>R. W.</given-names></name>; <name><surname>Mayxay</surname><given-names>M.</given-names></name>; <name><surname>Pongvongsa</surname><given-names>T.</given-names></name>; <name><surname>Phommasone</surname><given-names>K.</given-names></name>; <name><surname>Tripura</surname><given-names>R.</given-names></name>; <name><surname>Peto</surname><given-names>T. J.</given-names></name>; <name><surname>von Seidlein</surname><given-names>L.</given-names></name>; <name><surname>Nguon</surname><given-names>C.</given-names></name>; <name><surname>Lek</surname><given-names>D.</given-names></name>; <name><surname>Chan</surname><given-names>X. H. S.</given-names></name>; <name><surname>Rekol</surname><given-names>H.</given-names></name>; <name><surname>Leang</surname><given-names>R.</given-names></name>; <name><surname>Huch</surname><given-names>C.</given-names></name>; <name><surname>Kwiatkowski</surname><given-names>D. P.</given-names></name>; <name><surname>Miotto</surname><given-names>O.</given-names></name>; <name><surname>Ashley</surname><given-names>E. A.</given-names></name>; <name><surname>Kyaw</surname><given-names>M. P.</given-names></name>; <name><surname>Pukrittayakamee</surname><given-names>S.</given-names></name>; <name><surname>Day</surname><given-names>N. P. J.</given-names></name>; <name><surname>Dondorp</surname><given-names>A. M.</given-names></name>; <name><surname>Smithuis</surname><given-names>F. M.</given-names></name>; <name><surname>Nosten</surname><given-names>F. H.</given-names></name>; <name><surname>White</surname><given-names>N. J.</given-names></name>
<article-title>Molecular Epidemiology of Resistance to Antimalarial
Drugs in the Greater Mekong Subregion: An Observational Study</article-title>. <source>Lancet Infectious Diseases</source>
<year>2020</year>, <volume>20</volume> (<issue>12</issue>), <fpage>1470</fpage>&#x02013;<lpage>1480</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30228-0</pub-id>.<pub-id pub-id-type="pmid">32679084</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Uwimana</surname><given-names>A.</given-names></name>; <name><surname>Umulisa</surname><given-names>N.</given-names></name>; <name><surname>Venkatesan</surname><given-names>M.</given-names></name>; <name><surname>Svigel</surname><given-names>S. S.</given-names></name>; <name><surname>Zhou</surname><given-names>Z.</given-names></name>; <name><surname>Munyaneza</surname><given-names>T.</given-names></name>; <name><surname>Habimana</surname><given-names>R. M.</given-names></name>; <name><surname>Rucogoza</surname><given-names>A.</given-names></name>; <name><surname>Moriarty</surname><given-names>L. F.</given-names></name>; <name><surname>Sandford</surname><given-names>R.</given-names></name>; <name><surname>Piercefield</surname><given-names>E.</given-names></name>; <name><surname>Goldman</surname><given-names>I.</given-names></name>; <name><surname>Ezema</surname><given-names>B.</given-names></name>; <name><surname>Talundzic</surname><given-names>E.</given-names></name>; <name><surname>Pacheco</surname><given-names>M. A.</given-names></name>; <name><surname>Escalante</surname><given-names>A. A.</given-names></name>; <name><surname>Ngamije</surname><given-names>D.</given-names></name>; <name><surname>Mangala</surname><given-names>J.-L. N.</given-names></name>; <name><surname>Kabera</surname><given-names>M.</given-names></name>; <name><surname>Munguti</surname><given-names>K.</given-names></name>; <name><surname>Murindahabi</surname><given-names>M.</given-names></name>; <name><surname>Brieger</surname><given-names>W.</given-names></name>; <name><surname>Musanabaganwa</surname><given-names>C.</given-names></name>; <name><surname>Mutesa</surname><given-names>L.</given-names></name>; <name><surname>Udhayakumar</surname><given-names>V.</given-names></name>; <name><surname>Mbituyumuremyi</surname><given-names>A.</given-names></name>; <name><surname>Halsey</surname><given-names>E. S.</given-names></name>; <name><surname>Lucchi</surname><given-names>N. W.</given-names></name>
<article-title>Association of Plasmodium
Falciparum
Kelch13 R561H Genotypes with Delayed Parasite Clearance in Rwanda:
An Open-Label, Single-Arm, Multicentre, Therapeutic Efficacy Study</article-title>. <source>Lancet Infectious Diseases</source>
<year>2021</year>, <volume>21</volume> (<issue>8</issue>), <fpage>1120</fpage>&#x02013;<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(21)00142-0</pub-id>.<pub-id pub-id-type="pmid">33864801</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Antony</surname><given-names>H.</given-names></name>; <name><surname>Parija</surname><given-names>S.</given-names></name>
<article-title>Antimalarial Drug Resistance:
An Overview</article-title>. <source>Trop Parasitol</source>
<year>2016</year>, <volume>6</volume> (<issue>1</issue>), <fpage>30</fpage><pub-id pub-id-type="doi">10.4103/2229-5070.175081</pub-id>.<pub-id pub-id-type="pmid">26998432</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><article-title>Efficacy and Safety of RTS,S/AS01 Malaria Vaccine with or without
a Booster Dose in Infants and Children in Africa: Final Results of
a Phase 3, Individually Randomised, Controlled Trial</article-title>. <source>The Lancet</source>
<year>2015</year>, <volume>386</volume> (<issue>9988</issue>), <fpage>31</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60721-8</pub-id>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Datoo</surname><given-names>M. S.</given-names></name>; <name><surname>Natama</surname><given-names>M. H.</given-names></name>; <name><surname>Som&#x000e9;</surname><given-names>A.</given-names></name>; <name><surname>Traor&#x000e9;</surname><given-names>O.</given-names></name>; <name><surname>Rouamba</surname><given-names>T.</given-names></name>; <name><surname>Bellamy</surname><given-names>D.</given-names></name>; <name><surname>Yameogo</surname><given-names>P.</given-names></name>; <name><surname>Valia</surname><given-names>D.</given-names></name>; <name><surname>Tegneri</surname><given-names>M.</given-names></name>; <name><surname>Ouedraogo</surname><given-names>F.</given-names></name>; <name><surname>Soma</surname><given-names>R.</given-names></name>; <name><surname>Sawadogo</surname><given-names>S.</given-names></name>; <name><surname>Sorgho</surname><given-names>F.</given-names></name>; <name><surname>Derra</surname><given-names>K.</given-names></name>; <name><surname>Rouamba</surname><given-names>E.</given-names></name>; <name><surname>Orindi</surname><given-names>B.</given-names></name>; <name><surname>Ramos Lopez</surname><given-names>F.</given-names></name>; <name><surname>Flaxman</surname><given-names>A.</given-names></name>; <name><surname>Cappuccini</surname><given-names>F.</given-names></name>; <name><surname>Kailath</surname><given-names>R.</given-names></name>; <name><surname>Elias</surname><given-names>S.</given-names></name>; <name><surname>Mukhopadhyay</surname><given-names>E.</given-names></name>; <name><surname>Noe</surname><given-names>A.</given-names></name>; <name><surname>Cairns</surname><given-names>M.</given-names></name>; <name><surname>Lawrie</surname><given-names>A.</given-names></name>; <name><surname>Roberts</surname><given-names>R.</given-names></name>; <name><surname>Val&#x000e9;a</surname><given-names>I.</given-names></name>; <name><surname>Sorgho</surname><given-names>H.</given-names></name>; <name><surname>Williams</surname><given-names>N.</given-names></name>; <name><surname>Glenn</surname><given-names>G.</given-names></name>; <name><surname>Fries</surname><given-names>L.</given-names></name>; <name><surname>Reimer</surname><given-names>J.</given-names></name>; <name><surname>Ewer</surname><given-names>K. J.</given-names></name>; <name><surname>Shaligram</surname><given-names>U.</given-names></name>; <name><surname>Hill</surname><given-names>A. V. S.</given-names></name>; <name><surname>Tinto</surname><given-names>H.</given-names></name>
<article-title>Efficacy of a Low-Dose
Candidate
Malaria Vaccine, R21 in Adjuvant Matrix-M, with Seasonal Administration
to Children in Burkina Faso: A Randomised Controlled Trial</article-title>. <source>Lancet</source>
<year>2021</year>, <volume>397</volume> (<issue>10287</issue>), <fpage>1809</fpage>&#x02013;<lpage>1818</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00943-0</pub-id>.<pub-id pub-id-type="pmid">33964223</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Chandramohan</surname><given-names>D.</given-names></name>; <name><surname>Zongo</surname><given-names>I.</given-names></name>; <name><surname>Sagara</surname><given-names>I.</given-names></name>; <name><surname>Cairns</surname><given-names>M.</given-names></name>; <name><surname>Yerbanga</surname><given-names>R.-S.</given-names></name>; <name><surname>Diarra</surname><given-names>M.</given-names></name>; <name><surname>Niki&#x000e8;ma</surname><given-names>F.</given-names></name>; <name><surname>Tapily</surname><given-names>A.</given-names></name>; <name><surname>Sompougdou</surname><given-names>F.</given-names></name>; <name><surname>Issiaka</surname><given-names>D.</given-names></name>; <name><surname>Zoungrana</surname><given-names>C.</given-names></name>; <name><surname>Sanogo</surname><given-names>K.</given-names></name>; <name><surname>Haro</surname><given-names>A.</given-names></name>; <name><surname>Kaya</surname><given-names>M.</given-names></name>; <name><surname>Sienou</surname><given-names>A.-A.</given-names></name>; <name><surname>Traore</surname><given-names>S.</given-names></name>; <name><surname>Mahamar</surname><given-names>A.</given-names></name>; <name><surname>Thera</surname><given-names>I.</given-names></name>; <name><surname>Diarra</surname><given-names>K.</given-names></name>; <name><surname>Dolo</surname><given-names>A.</given-names></name>; <name><surname>Kuepfer</surname><given-names>I.</given-names></name>; <name><surname>Snell</surname><given-names>P.</given-names></name>; <name><surname>Milligan</surname><given-names>P.</given-names></name>; <name><surname>Ockenhouse</surname><given-names>C.</given-names></name>; <name><surname>Ofori-Anyinam</surname><given-names>O.</given-names></name>; <name><surname>Tinto</surname><given-names>H.</given-names></name>; <name><surname>Djimde</surname><given-names>A.</given-names></name>; <name><surname>Ou&#x000e9;draogo</surname><given-names>J.-B.</given-names></name>; <name><surname>Dicko</surname><given-names>A.</given-names></name>; <name><surname>Greenwood</surname><given-names>B.</given-names></name>
<article-title>Seasonal Malaria
Vaccination with
or without Seasonal Malaria Chemoprevention</article-title>. <source>N Engl J. Med.</source>
<year>2021</year>, <volume>385</volume> (<issue>11</issue>), <fpage>1005</fpage>&#x02013;<lpage>1017</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2026330</pub-id>.<pub-id pub-id-type="pmid">34432975</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Plouffe</surname><given-names>D.</given-names></name>; <name><surname>Brinker</surname><given-names>A.</given-names></name>; <name><surname>McNamara</surname><given-names>C.</given-names></name>; <name><surname>Henson</surname><given-names>K.</given-names></name>; <name><surname>Kato</surname><given-names>N.</given-names></name>; <name><surname>Kuhen</surname><given-names>K.</given-names></name>; <name><surname>Nagle</surname><given-names>A.</given-names></name>; <name><surname>Adri&#x000e1;n</surname><given-names>F.</given-names></name>; <name><surname>Matzen</surname><given-names>J. T.</given-names></name>; <name><surname>Anderson</surname><given-names>P.</given-names></name>; <name><surname>Nam</surname><given-names>T.</given-names></name>; <name><surname>Gray</surname><given-names>N. S.</given-names></name>; <name><surname>Chatterjee</surname><given-names>A.</given-names></name>; <name><surname>Janes</surname><given-names>J.</given-names></name>; <name><surname>Yan</surname><given-names>S. F.</given-names></name>; <name><surname>Trager</surname><given-names>R.</given-names></name>; <name><surname>Caldwell</surname><given-names>J. S.</given-names></name>; <name><surname>Schultz</surname><given-names>P. G.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Winzeler</surname><given-names>E. A.</given-names></name>
<article-title><italic>In Silico</italic> Activity Profiling Reveals
the Mechanism of Action
of Antimalarials Discovered in a High-Throughput Screen</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2008</year>, <volume>105</volume> (<issue>26</issue>), <fpage>9059</fpage>&#x02013;<lpage>9064</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0802982105</pub-id>.<pub-id pub-id-type="pmid">18579783</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Gamo</surname><given-names>F.-J.</given-names></name>; <name><surname>Sanz</surname><given-names>L. M.</given-names></name>; <name><surname>Vidal</surname><given-names>J.</given-names></name>; <name><surname>de Cozar</surname><given-names>C.</given-names></name>; <name><surname>Alvarez</surname><given-names>E.</given-names></name>; <name><surname>Lavandera</surname><given-names>J.-L.</given-names></name>; <name><surname>Vanderwall</surname><given-names>D. E.</given-names></name>; <name><surname>Green</surname><given-names>D. V. S.</given-names></name>; <name><surname>Kumar</surname><given-names>V.</given-names></name>; <name><surname>Hasan</surname><given-names>S.</given-names></name>; <name><surname>Brown</surname><given-names>J. R.</given-names></name>; <name><surname>Peishoff</surname><given-names>C. E.</given-names></name>; <name><surname>Cardon</surname><given-names>L. R.</given-names></name>; <name><surname>Garcia-Bustos</surname><given-names>J. F.</given-names></name>
<article-title>Thousands
of Chemical Starting Points for Antimalarial
Lead Identification</article-title>. <source>Nature</source>
<year>2010</year>, <volume>465</volume> (<issue>7296</issue>), <fpage>305</fpage>&#x02013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1038/nature09107</pub-id>.<pub-id pub-id-type="pmid">20485427</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Guiguemde</surname><given-names>W. A.</given-names></name>; <name><surname>Shelat</surname><given-names>A. A.</given-names></name>; <name><surname>Bouck</surname><given-names>D.</given-names></name>; <name><surname>Duffy</surname><given-names>S.</given-names></name>; <name><surname>Crowther</surname><given-names>G. J.</given-names></name>; <name><surname>Davis</surname><given-names>P. H.</given-names></name>; <name><surname>Smithson</surname><given-names>D. C.</given-names></name>; <name><surname>Connelly</surname><given-names>M.</given-names></name>; <name><surname>Clark</surname><given-names>J.</given-names></name>; <name><surname>Zhu</surname><given-names>F.</given-names></name>; <name><surname>Jim&#x000e9;nez-D&#x000ed;az</surname><given-names>M. B.</given-names></name>; <name><surname>Martinez</surname><given-names>M. S.</given-names></name>; <name><surname>Wilson</surname><given-names>E. B.</given-names></name>; <name><surname>Tripathi</surname><given-names>A. K.</given-names></name>; <name><surname>Gut</surname><given-names>J.</given-names></name>; <name><surname>Sharlow</surname><given-names>E. R.</given-names></name>; <name><surname>Bathurst</surname><given-names>I.</given-names></name>; <name><surname>Mazouni</surname><given-names>F. E.</given-names></name>; <name><surname>Fowble</surname><given-names>J. W.</given-names></name>; <name><surname>Forquer</surname><given-names>I.</given-names></name>; <name><surname>McGinley</surname><given-names>P. L.</given-names></name>; <name><surname>Castro</surname><given-names>S.</given-names></name>; <name><surname>Angulo-Barturen</surname><given-names>I.</given-names></name>; <name><surname>Ferrer</surname><given-names>S.</given-names></name>; <name><surname>Rosenthal</surname><given-names>P. J.</given-names></name>; <name><surname>DeRisi</surname><given-names>J. L.</given-names></name>; <name><surname>Sullivan</surname><given-names>D. J.</given-names></name>; <name><surname>Lazo</surname><given-names>J. S.</given-names></name>; <name><surname>Roos</surname><given-names>D. S.</given-names></name>; <name><surname>Riscoe</surname><given-names>M. K.</given-names></name>; <name><surname>Phillips</surname><given-names>M. A.</given-names></name>; <name><surname>Rathod</surname><given-names>P. K.</given-names></name>; <name><surname>Van Voorhis</surname><given-names>W. C.</given-names></name>; <name><surname>Avery</surname><given-names>V. M.</given-names></name>; <name><surname>Guy</surname><given-names>R. K.</given-names></name>
<article-title>Chemical
Genetics of Plasmodium Falciparum</article-title>. <source>Nature</source>
<year>2010</year>, <volume>465</volume> (<issue>7296</issue>), <fpage>311</fpage>&#x02013;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1038/nature09099</pub-id>.<pub-id pub-id-type="pmid">20485428</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Phillips</surname><given-names>M. A.</given-names></name>; <name><surname>Burrows</surname><given-names>J. N.</given-names></name>; <name><surname>Manyando</surname><given-names>C.</given-names></name>; <name><surname>van Huijsduijnen</surname><given-names>R. H.</given-names></name>; <name><surname>Van Voorhis</surname><given-names>W. C.</given-names></name>; <name><surname>Wells</surname><given-names>T. N. C.</given-names></name>
<article-title>Malaria</article-title>. <source>Nature
Reviews Disease Primers</source>
<year>2017</year>, <volume>3</volume> (<issue>1</issue>), <elocation-id>17050</elocation-id><pub-id pub-id-type="doi">10.1038/nrdp.2017.50</pub-id>.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Cumming</surname><given-names>J. G.</given-names></name>; <name><surname>Davis</surname><given-names>A. M.</given-names></name>; <name><surname>Muresan</surname><given-names>S.</given-names></name>; <name><surname>Haeberlein</surname><given-names>M.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>
<article-title>Chemical Predictive Modelling to
Improve Compound Quality</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2013</year>, <volume>12</volume> (<issue>12</issue>), <fpage>948</fpage>&#x02013;<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1038/nrd4128</pub-id>.<pub-id pub-id-type="pmid">24287782</pub-id>
</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Vamathevan</surname><given-names>J.</given-names></name>; <name><surname>Clark</surname><given-names>D.</given-names></name>; <name><surname>Czodrowski</surname><given-names>P.</given-names></name>; <name><surname>Dunham</surname><given-names>I.</given-names></name>; <name><surname>Ferran</surname><given-names>E.</given-names></name>; <name><surname>Lee</surname><given-names>G.</given-names></name>; <name><surname>Li</surname><given-names>B.</given-names></name>; <name><surname>Madabhushi</surname><given-names>A.</given-names></name>; <name><surname>Shah</surname><given-names>P.</given-names></name>; <name><surname>Spitzer</surname><given-names>M.</given-names></name>; <name><surname>Zhao</surname><given-names>S.</given-names></name>
<article-title>Applications
of Machine Learning in Drug Discovery and Development</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2019</year>, <volume>18</volume> (<issue>6</issue>), <fpage>463</fpage>&#x02013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-019-0024-5</pub-id>.<pub-id pub-id-type="pmid">30976107</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Jim&#x000e9;nez-Luna</surname><given-names>J.</given-names></name>; <name><surname>Grisoni</surname><given-names>F.</given-names></name>; <name><surname>Schneider</surname><given-names>G.</given-names></name>
<article-title>Drug Discovery
with Explainable Artificial
Intelligence</article-title>. <source>Nat. Mach Intell</source>
<year>2020</year>, <volume>2</volume> (<issue>10</issue>), <fpage>573</fpage>&#x02013;<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1038/s42256-020-00236-4</pub-id>.</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Keshavarzi
Arshadi</surname><given-names>A.</given-names></name>; <name><surname>Salem</surname><given-names>M.</given-names></name>; <name><surname>Collins</surname><given-names>J.</given-names></name>; <name><surname>Yuan</surname><given-names>J. S.</given-names></name>; <name><surname>Chakrabarti</surname><given-names>D.</given-names></name>
<article-title>DeepMalaria: Artificial Intelligence Driven Discovery
of Potent Antiplasmodials</article-title>. <source>Front. Pharmacol.</source>
<year>2020</year>, <volume>10</volume>, <fpage>1526</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.01526</pub-id>.<pub-id pub-id-type="pmid">32009951</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Tse</surname><given-names>E. G.</given-names></name>; <name><surname>Aithani</surname><given-names>L.</given-names></name>; <name><surname>Anderson</surname><given-names>M.</given-names></name>; <name><surname>Cardoso-Silva</surname><given-names>J.</given-names></name>; <name><surname>Cincilla</surname><given-names>G.</given-names></name>; <name><surname>Conduit</surname><given-names>G. J.</given-names></name>; <name><surname>Galushka</surname><given-names>M.</given-names></name>; <name><surname>Guan</surname><given-names>D.</given-names></name>; <name><surname>Hallyburton</surname><given-names>I.</given-names></name>; <name><surname>Irwin</surname><given-names>B. W. J.</given-names></name>; <name><surname>Kirk</surname><given-names>K.</given-names></name>; <name><surname>Lehane</surname><given-names>A. M.</given-names></name>; <name><surname>Lindblom</surname><given-names>J. C. R.</given-names></name>; <name><surname>Lui</surname><given-names>R.</given-names></name>; <name><surname>Matthews</surname><given-names>S.</given-names></name>; <name><surname>McCulloch</surname><given-names>J.</given-names></name>; <name><surname>Motion</surname><given-names>A.</given-names></name>; <name><surname>Ng</surname><given-names>H. L.</given-names></name>; <name><surname>&#x000d6;eren</surname><given-names>M.</given-names></name>; <name><surname>Robertson</surname><given-names>M. N.</given-names></name>; <name><surname>Spadavecchio</surname><given-names>V.</given-names></name>; <name><surname>Tatsis</surname><given-names>V. A.</given-names></name>; <name><surname>van Hoorn</surname><given-names>W. P.</given-names></name>; <name><surname>Wade</surname><given-names>A. D.</given-names></name>; <name><surname>Whitehead</surname><given-names>T. M.</given-names></name>; <name><surname>Willis</surname><given-names>P.</given-names></name>; <name><surname>Todd</surname><given-names>M. H.</given-names></name>
<article-title>An Open
Drug Discovery Competition: Experimental Validation of Predictive
Models in a Series of Novel Antimalarials</article-title>. <source>J.
Med. Chem.</source>
<year>2021</year>, <volume>64</volume> (<issue>22</issue>), <fpage>16450</fpage>&#x02013;<lpage>16463</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00313</pub-id>.<pub-id pub-id-type="pmid">34748707</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Verras</surname><given-names>A.</given-names></name>; <name><surname>Waller</surname><given-names>C. L.</given-names></name>; <name><surname>Gedeck</surname><given-names>P.</given-names></name>; <name><surname>Green</surname><given-names>D. V. S.</given-names></name>; <name><surname>Kogej</surname><given-names>T.</given-names></name>; <name><surname>Raichurkar</surname><given-names>A.</given-names></name>; <name><surname>Panda</surname><given-names>M.</given-names></name>; <name><surname>Shelat</surname><given-names>A. A.</given-names></name>; <name><surname>Clark</surname><given-names>J.</given-names></name>; <name><surname>Guy</surname><given-names>R. K.</given-names></name>; <name><surname>Papadatos</surname><given-names>G.</given-names></name>; <name><surname>Burrows</surname><given-names>J.</given-names></name>
<article-title>Shared Consensus Machine
Learning Models for Predicting Blood Stage Malaria Inhibition</article-title>. <source>J. Chem. Inf. Model.</source>
<year>2017</year>, <volume>57</volume> (<issue>3</issue>), <fpage>445</fpage>&#x02013;<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00572</pub-id>.<pub-id pub-id-type="pmid">28257198</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Bosc</surname><given-names>N.</given-names></name>; <name><surname>Felix</surname><given-names>E.</given-names></name>; <name><surname>Arcila</surname><given-names>R.</given-names></name>; <name><surname>Mendez</surname><given-names>D.</given-names></name>; <name><surname>Saunders</surname><given-names>M. R.</given-names></name>; <name><surname>Green</surname><given-names>D. V. S.</given-names></name>; <name><surname>Ochoada</surname><given-names>J.</given-names></name>; <name><surname>Shelat</surname><given-names>A. A.</given-names></name>; <name><surname>Martin</surname><given-names>E. J.</given-names></name>; <name><surname>Iyer</surname><given-names>P.</given-names></name>; <name><surname>Engkvist</surname><given-names>O.</given-names></name>; <name><surname>Verras</surname><given-names>A.</given-names></name>; <name><surname>Duffy</surname><given-names>J.</given-names></name>; <name><surname>Burrows</surname><given-names>J.</given-names></name>; <name><surname>Gardner</surname><given-names>J. M. F.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name>
<article-title>MAIP: A Web Service
for Predicting Blood-stage Malaria Inhibitors</article-title>. <source>J. Cheminform</source>
<year>2021</year>, <volume>13</volume> (<issue>1</issue>), <fpage>13</fpage><pub-id pub-id-type="doi">10.1186/s13321-021-00487-2</pub-id>.<pub-id pub-id-type="pmid">33618772</pub-id>
</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Baell</surname><given-names>J. B.</given-names></name>; <name><surname>Holloway</surname><given-names>G. A.</given-names></name>
<article-title>New Substructure Filters for Removal
of Pan Assay Interference
Compounds (PAINS) from Screening Libraries and for Their Exclusion
in Bioassays</article-title>. <source>J. Med. Chem.</source>
<year>2010</year>, <volume>53</volume> (<issue>7</issue>), <fpage>2719</fpage>&#x02013;<lpage>2740</lpage>. <pub-id pub-id-type="doi">10.1021/jm901137j</pub-id>.<pub-id pub-id-type="pmid">20131845</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>van
der Matten</surname><given-names>L.</given-names></name>; <name><surname>Hinton</surname><given-names>G.</given-names></name>
<article-title>Visualizing Data Using T-SNE</article-title>. <source>Journal of Machine Learning Research</source>
<year>2008</year>, <volume>9</volume>, <fpage>2579</fpage>&#x02013;<lpage>2605</lpage>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Dechering</surname><given-names>K. J.</given-names></name>; <name><surname>Timmerman</surname><given-names>M.</given-names></name>; <name><surname>Rensen</surname><given-names>K.</given-names></name>; <name><surname>Koolen</surname><given-names>K. M. J.</given-names></name>; <name><surname>Honarnejad</surname><given-names>S.</given-names></name>; <name><surname>Vos</surname><given-names>M. W.</given-names></name>; <name><surname>Huijs</surname><given-names>T.</given-names></name>; <name><surname>Henderson</surname><given-names>R. W. M.</given-names></name>; <name><surname>Chenu</surname><given-names>E.</given-names></name>; <name><surname>Laleu</surname><given-names>B.</given-names></name>; <name><surname>Montefiore</surname><given-names>B. C.</given-names></name>; <name><surname>Segall</surname><given-names>M. D.</given-names></name>; <name><surname>Mills</surname><given-names>J. E. J.</given-names></name>; <name><surname>Guantai</surname><given-names>E. M.</given-names></name>; <name><surname>Duffy</surname><given-names>J.</given-names></name>; <name><surname>Duffey</surname><given-names>M.</given-names></name>
<article-title>Replenishing the Malaria Drug Discovery Pipeline: Screening
and Hit Evaluation of the MMV Hit Generation Library 1 (HGL1) against
Asexual Blood Stage Plasmodium Falciparum, Using a Nano Luciferase
Reporter Read-Out</article-title>. <source>SLAS Discovery</source>
<year>2022</year>, <volume>27</volume>, <fpage>337</fpage>&#x02013;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1016/j.slasd.2022.07.002</pub-id>.<pub-id pub-id-type="pmid">35872229</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Segler</surname><given-names>M. H. S.</given-names></name>; <name><surname>Kogej</surname><given-names>T.</given-names></name>; <name><surname>Tyrchan</surname><given-names>C.</given-names></name>; <name><surname>Waller</surname><given-names>M. P.</given-names></name>
<article-title>Generating Focused
Molecule Libraries for Drug Discovery with Recurrent Neural Networks</article-title>. <source>ACS Cent. Sci.</source>
<year>2018</year>, <volume>4</volume> (<issue>1</issue>), <fpage>120</fpage>&#x02013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.7b00512</pub-id>.<pub-id pub-id-type="pmid">29392184</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Walters</surname><given-names>W. P.</given-names></name>; <name><surname>Murcko</surname><given-names>M.</given-names></name>
<article-title>Assessing the Impact
of Generative AI on Medicinal
Chemistry</article-title>. <source>Nat. Biotechnol.</source>
<year>2020</year>, <volume>38</volume> (<issue>2</issue>), <fpage>143</fpage>&#x02013;<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-020-0418-2</pub-id>.<pub-id pub-id-type="pmid">32001834</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Zhavoronkov</surname><given-names>A.</given-names></name>; <name><surname>Aspuru-Guzik</surname><given-names>A.</given-names></name>
<article-title>Reply to &#x02018;Assessing
the Impact of Generative
AI on Medicinal Chemistry.&#x02019;</article-title>. <source>Nat. Biotechnol.</source>
<year>2020</year>, <volume>38</volume> (<issue>2</issue>), <fpage>146</fpage>&#x02013;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-020-0417-3</pub-id>.<pub-id pub-id-type="pmid">32001835</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Thomas</surname><given-names>M.</given-names></name>; <name><surname>Smith</surname><given-names>R. T.</given-names></name>; <name><surname>O&#x02019;Boyle</surname><given-names>N. M.</given-names></name>; <name><surname>de Graaf</surname><given-names>C.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>
<article-title>Comparison
of Structure- and Ligand-Based Scoring Functions for Deep Generative
Models: A GPCR Case Study</article-title>. <source>J. Cheminform</source>
<year>2021</year>, <volume>13</volume> (<issue>1</issue>), <fpage>39</fpage><pub-id pub-id-type="doi">10.1186/s13321-021-00516-0</pub-id>.<pub-id pub-id-type="pmid">33985583</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Bilodeau</surname><given-names>C.</given-names></name>; <name><surname>Jin</surname><given-names>W.</given-names></name>; <name><surname>Jaakkola</surname><given-names>T.</given-names></name>; <name><surname>Barzilay</surname><given-names>R.</given-names></name>; <name><surname>Jensen</surname><given-names>K. F.</given-names></name>
<article-title>Generative Models
for Molecular Discovery: Recent Advances and Challenges</article-title>. <source>WIREs Comput. Mol. Sci.</source>
<year>2022</year>, <volume>12</volume> (<issue>5</issue>), <fpage>e1608</fpage><pub-id pub-id-type="doi">10.1002/wcms.1608</pub-id>.</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Mendez</surname><given-names>D.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>De Veij</surname><given-names>M.</given-names></name>; <name><surname>F&#x000e9;lix</surname><given-names>E.</given-names></name>; <name><surname>Magari&#x000f1;os</surname><given-names>M. P.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Mutowo</surname><given-names>P.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; <name><surname>Gordillo-Mara&#x000f1;&#x000f3;n</surname><given-names>M.</given-names></name>; <name><surname>Hunter</surname><given-names>F.</given-names></name>; <name><surname>Junco</surname><given-names>L.</given-names></name>; <name><surname>Mugumbate</surname><given-names>G.</given-names></name>; <name><surname>Rodriguez-Lopez</surname><given-names>M.</given-names></name>; <name><surname>Atkinson</surname><given-names>F.</given-names></name>; <name><surname>Bosc</surname><given-names>N.</given-names></name>; <name><surname>Radoux</surname><given-names>C. J.</given-names></name>; <name><surname>Segura-Cabrera</surname><given-names>A.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name>
<article-title>ChEMBL: Towards
Direct Deposition of Bioassay Data</article-title>. <source>Nucleic
Acids Res.</source>
<year>2019</year>, <volume>47</volume> (<issue>D1</issue>), <fpage>D930</fpage>&#x02013;<lpage>D940</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id>.<pub-id pub-id-type="pmid">30398643</pub-id>
</mixed-citation></ref></ref-list></back></article>
